Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T13:35:16.552Z.
Consensus retrieved: 2026-10-06T08:18:19.856Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:35:16.552Z.
Quote observation: 2026-10-06T13:31:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 374a47b91f4df6a230cb26954d8d957a3b546ee3094b4b70ca7ed529159f4796
Forward PE Ratio (N/A) = Dated Quote Price ($1.01) / Consensus Forward EPS ($1.30)
FORWARD PE RATIO
N/A
ABVC BioPharma, Inc.
Market Cap
$26.22M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ABVC BioPharma, Inc. (ABVC) | $26.22M | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.65M | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.54M | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.60M | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.24M | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A |
| LeonaBio, Inc. (LONA)vs › | $21.89M | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $30.81M | 9.13 |
| CervoMed Inc. (CRVO)vs › | $31.11M | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $31.14M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.01, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.30 | $1.30 – $1.30 | 1 | 0.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
